Palliative Subcutaneous Terbutaline Infusion in Severe Asthma.
Continuous subcutaneous infusion of terbutaline (CSIT) has been shown to improve asthma control. As an adjunct to standard asthma pharmacotherapy, 3-12mg/day of CSIT can stabilise asthmatic symptoms, reduce hospitalisations and reduce corticosteroid need1,2. Asthmatics who demonstrate a wide diurnal variability in their peak-flows (>40%), termed brittle asthmatics tend to benefit the most from this therapy3. CSIT can have adverse effects and should only be used in specialist respiratory centres.
Department of Respiratory Medicine, AMNCH, Tallaght, Dublin 24.
A
A
Sahadevan
Department of Respiratory Medicine, AMNCH, Tallaght, Dublin 24.
S J
SJ
Lane